Cisplatin, mitomycin, and interferon-α2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma

Chest

Volumn 116, Issue 2, 1999, Pages 391-398

  Metintas, Muzaffer ^a,b   Özdemir, Necla ^a   Uçgun, Irfan ^a   Elbek, Osman ^a   Kolsuz, Mustafa ^a   Mutlu, Sevda ^a   Metintas, Selma ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

^b NONE   (Turkey)

Author keywords

Chemotherapy; Cisplatin; Interferon a Mesothelioma; Mitomycin; Therapy

Indexed keywords

ALPHA2 INTERFERON; ASBESTOS; CISPLATIN; MITOMYCIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASBESTOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TOLERANCE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; MALE; PATIENT COMPLIANCE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0032774035     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.2.391     Document Type: Article

References (38)

1. Hillerdal G. Pleural malignancies including mesothelioma. Curr Opin Pulm Med 1995; 1:339-343
2. Selcuk ZT, Coplu L, Emri S, et al. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey: analysis of 135 cases. Chest 1992; 102:790-796
3. Baris YI. Asbestos and erionite related chest diseases. Ankara, Turkey: Semih Ofset Matbaacilik Ltd Company, 1987; 8-139
4. McDonald JC. Health implications of environmental exposure to asbestos. Environ Health Perspect 1985; 62:319-328
5. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6:527-535
6. Vogelzang NJ. Malignant mesothelioma: diagnostic and management strategies for 1992. Semin Oncol 1992; 19:64-71
7. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits [review]? Chest 1995; 107(suppl):345S-350S
8. Sugarbaker DJ, Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest 1998; 113(suppl):61S-65S
9. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998; 113(suppl):66S-73S
10. Hunt KJ, Longton G, Williams MA, et al. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 1996; 109:1239-1242
11. Bowman RV, Manning LS, Davis MR, et al. Chemosensitivity and cytokine sensitivity of malignant mesothelioma. Cancer Chemother Pharmacol 1981; 28:420-426
12. Christmas TI, Manning LS, Garlepp MJ, et al. Effect of interferon alpha 2a on malignant mesothelioma. J Interferon Res 1993; 13:9-12
13. Ardizzoni A, Penucci MC, Castagneto B, et al. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 1994; 17:80-82
14. Uphan JW, Musk AW, van Hazel G, et al. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med 1993; 23:683-687
15. Soulié P, Ruffié P, Trandafir L, et al. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 1996; 14:878-885
16. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50:3473-3486
17. Chahinian AP, Norton L, Holland JF, et al. Experimental and clinical activity of mitomycine-C and cis-diamminodichloroplatinum in malignant mesothelioma. Cancer Res 1984; 44:1688-1692
18. Sklarin NT, Chahinian AP, Feuer EJ, et al. Augmentation of activity of cis-diamminodichloroplatinum (II) and mitomycine C by interferon in human malignant xenografts in nude mice. Cancer Res 1988; 48:64-67
19. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995; 107(suppl):332S-344S
20. Rusch VS, Ginsberg RJ. New concepts in the staging of mesotheliomas. In: Deslauriers J, Lacquet LK, eds. International Trends in General Thoracic Surgery. St. Louis, MO: CV Mosby, 1990; 336-343
21. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214
22. Ruffié P. Mesothelioma chemotherapy. Eur Respir Rev 1993; 3:194-203
23. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997; 63:334-338
24. Vogelzang NJ, Weissman LB, Herndon JE, et al. Trimetrexate in malignant mesothelioma: a cancer and leukemia group B phase II study. J Clin Oncol 1994; 12:1436-1442
25. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996; 14:1007-1017
26. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycine in malignant mesothelioma. Cancer Treat Rep 1987; 71:857-858
27. Zidar BL, Green S, Pierce HI, et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 1988; 6:223-226
28. Van Breukelen FJM, Mattson K, Giaccone G, et al. Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1991; 27:1629-1633
29. Meerbeeck JV, Debruyne C, Zandwijk NV, et al. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996; 74:961-963
30. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycine or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group. Br J Clin Oncol 1993; 11:1559-1565
31. Einhor S, Strander H. Interferon therapy for neoplastic diseases in man in vitro and in vivo. Adv Exp Med Biol 1987; 110:159-174
32. Foon KA. Biological response modifiers: the new immunotherapy. Cancer Res 1989; 49:1621-1639
33. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model. J Interferon Cytokine Res 1995; 15:213-223
34. Wivel NA, Pitha PM. Interferon treatment of meth-A sarcoma cell effects on the malignant phenotype and expression of tumour specific and H2 antigens. Int J Cancer 1982; 30:649-654
35. Belardelli F, Gresser I, Maury C, et al. Antitumour effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. Int J Cancer 1982; 30:813-820
36. Balkwill FR, Mowshowitz S, Seilmain SS, et al. Positive interactions between interferon and chemotherapy due to direct tumor action rather then effects on host drug-metabolizing enzymes. Cancer Res 1984; 44:5249-5255
37. Tansan S, Emri S, Selçuk T, et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycine C and alpha interferon. Oncology 1994; 51:348-351
38. Shin DM, Fossella FB, Umsawardi T, et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1995; 76:2230-2236